| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.avonlifesciences.com | |
| Market Cap | 9.77 Cr. | |
| Enterprise Value(EV) | 149.33 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -2.29 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.01 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | -55.26 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | -0.07 | Calculated using Price: 4.10 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 2.38 Cr. | 23,825,000 Shares |
| FaceValue | 10 | |
| About Kobo Biotech Ltd. | ||
| AVON Organics Limited (AOL) was started by P R Agarwal, Rajesh Agarwal along with late G S Sidhu .It is located at Madhupala Towers Greenlands, Hyderabad 500 016, India. The company's transition from a machinery manufacturer to a full-fledged chemical manufacturer saw the company foraying into the highly technology-intensive area of Diketene and its derivatives. | ||
| 1 Day |
|
|
| 1 Week |
|
-0.49% |
| 1 Month |
|
-5.75% |
| 3 Month |
|
+11.41% |
| 6 Month |
|
+51.85% |
| 1 Year |
|
+53.56% |
| 2 Year |
|
-31.67% |
| 5 Year |
|
-13.68% |
| 10 Year |
|
-61.54% |
| 9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -103.9 | -233.98 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Return on Capital Employed (%) | -8.67 | -1.32 | -2.78 | -5.12 | -5.74 | -3.93 | -5.31 | -17.59 | -36.84 | |
| Return on Assets (%) | -11.4 | -6.43 | -7.5 | -9.6 | -10.08 | -8.83 | -8.24 | -9.83 | -7.19 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 14 | 6 | -19 | -43 | -67 | -88 | -107 | -122 | -128 | -130 | |
| Non Curr. Liab. | 74 | 74 | 64 | 47 | 40 | 40 | 39 | 38 | 37 | 37 | |
| Curr. Liab. | 164 | 180 | 207 | 242 | 266 | 284 | 299 | 163 | 166 | 166 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 252 | 260 | 252 | 246 | 239 | 236 | 231 | 79 | 75 | 73 | |
| Non Curr. Assets | 110 | 102 | 95 | 89 | 83 | 77 | 71 | 42 | 38 | 36 | |
| Curr. Assets | 142 | 158 | 157 | 157 | 157 | 159 | 159 | 38 | 38 | 38 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 252 | 260 | 252 | 246 | 239 | 236 | 231 | 79 | 75 | 73 |
| Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 29 | 33 | |||||||||
| Other Income | 1 | 1 | 6 | 0 | 1 | 2 | 0 | 133 | 0 | 0 | |
| Total Income | 30 | 34 | 6 | 0 | 1 | 2 | 0 | 133 | 0 | 0 | |
| Total Expenditure | -39 | -29 | -4 | -3 | -3 | -3 | -3 | -144 | -2 | -1 | |
| PBIDT | -9 | 5 | 2 | -3 | -2 | -1 | -3 | -10 | -1 | -1 | |
| Interest | -16 | -14 | -14 | -15 | -14 | -14 | -11 | 0 | |||
| Depreciation | -8 | -7 | -7 | -6 | -6 | -6 | -6 | -5 | -4 | -4 | |
| Taxation | |||||||||||
| Exceptional Items | 3 | -2 | |||||||||
| PAT | -30 | -16 | -19 | -24 | -24 | -21 | -19 | -15 | -6 | -5 | |
| Adjusted EPS | -13 | -7 | -8 | -10 | -10 | -9 | -8 | -6 | -2 | -2 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 11 | 19 | 6 | 32 | 31 | 21 | 14 | 3 | 94 | 1 | |
| Cash Fr. Inv. | -5 | 25 | |||||||||
| Cash Fr. Finan. | -7 | -21 | -5 | -33 | -31 | -21 | -14 | -1 | -120 | -1 | |
| Net Change | -1 | -1 | 0 | 0 | 1 | -1 | |||||
| Cash & Cash Eqvt | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
|
Thu, 28 Mar 2024
Closure of Trading Window The trading window for dealing in the securities of the Company will remain closed from 1st April 2024 till the conclusion of 48 hrs from the Declaration of Financial Results for the quarter ended 31st March 2024. |
|
Wed, 14 Feb 2024
Financial Result For The Quarter And Nine Months Ended 31St December 2023 Financial Results for the Quarter and Nine Months ended 31st December 2023 |
|
Wed, 07 Feb 2024
Board Meeting Intimation for Approval Of The Unaudited Financial Statements For The Quarter And Nine Months Ended 31St December 2023. Kobo Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve the unaudited financial statements for the quarter and nine months ended 31st December 2023 |
| Thu, 18 Apr 2024 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
